Vera Therapeutics (VERA) to Release Earnings on Thursday

Vera Therapeutics (NASDAQ:VERA - Get Free Report) is expected to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.75) per share for the quarter.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.06). During the same quarter last year, the business earned ($0.56) earnings per share. On average, analysts expect Vera Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Vera Therapeutics Price Performance

NASDAQ VERA traded down $3.52 during trading on Tuesday, hitting $22.01. 4,144,052 shares of the company's stock were exchanged, compared to its average volume of 769,396. The company has a market cap of $1.40 billion, a PE ratio of -8.43 and a beta of 1.28. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17. Vera Therapeutics has a fifty-two week low of $18.53 and a fifty-two week high of $51.61. The stock's 50 day moving average price is $24.63 and its two-hundred day moving average price is $35.06.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on VERA shares. Wolfe Research initiated coverage on shares of Vera Therapeutics in a research note on Tuesday, February 4th. They issued an "outperform" rating and a $49.00 price objective for the company. Guggenheim raised their price objective on Vera Therapeutics from $59.00 to $61.00 and gave the company a "buy" rating in a report on Thursday, February 27th. JPMorgan Chase & Co. lowered their target price on Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating for the company in a report on Tuesday, March 4th. HC Wainwright began coverage on Vera Therapeutics in a research note on Monday. They set a "buy" rating and a $75.00 price target on the stock. Finally, The Goldman Sachs Group assumed coverage on shares of Vera Therapeutics in a report on Tuesday, January 28th. They set a "buy" rating and a $58.00 target price on the stock. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat, Vera Therapeutics presently has an average rating of "Buy" and an average target price of $65.70.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.